Ⅱ期羟基磷灰石义眼座眶内植入治疗眼球摘除后畸形综合征疗效观察

目的探讨对已摘除眼球后造成眼窝塌陷的病例施行Ⅱ期羟基磷灰石(hydroxyapatite,HA)义眼座眼窝植入的临床效果。方法对22例已行眼球摘除的患者,进行Ⅱ期有或无巩膜包裹羟基磷灰石义眼座植入。追踪观察3~12个月。结果植入HA义眼座球体稳定,眼眶饱满,义眼座活动度好,无严重的球体暴露脱出及移位。结论Ⅱ期羟基磷灰石义眼座眼窝内植入术后外观满意,并发症少,病程长短不限,是治疗眼球摘除术后眼窝凹陷畸形的理想方法。     

羟基磷灰石义眼座植入同期结膜囊缩窄成形术

目的 观察羟基磷灰石义眼座植入同时结膜囊成形的效果。方法 19例眼球严重损害同时伴部分结膜囊缩窄19眼。在眼内容摘除，羟基磷灰石义眼座植入的同时行唇粘膜移植结膜囊成形术。结果 全部19眼唇粘膜移植成功。结膜囊成形良好，未见并发症。结论 对部分结膜囊缩窄患者，可在羟基磷灰石义眼座植入的同时行结膜囊成形术。     

羟基磷灰石义眼座植入治疗眼窝凹陷畸形31例

目的 羟基磷灰石(hydroxyaatite,HA)义眼座作为眶内填充物，矫正各种原因所致眼窝凹陷畸形的临床观察。方法 对3l例眼球摘除眼窝凹陷患者，行自体或异体巩膜包裹HA义眼座植入肌锥内，四直肌固定在前部义眼座壁上，分层缝合筋膜与结膜，结膜囊装入薄眼膜，常规挟药拆线，4～6周后配装义眼片。结果有28例患眼术后结膜创口Ⅰ期愈合，2例结膜创口哆裂，经修补Ⅱ期愈合，1例创口溃烂、排脓，HA义眼座取出后抗炎治疗，创口愈合。结论HA义眼座具有良好的组织相容性及理论稳定性，无毒不吸收，是目前较为理想的眶内填充材料。利用它治疗眼窝凹陷畸形，方法简便，效果满意。     

眼球摘除联合羟基磷灰石义眼座植入的临床体会

目的探讨眼球摘除手术后,羟基磷灰石义眼座植入方法。方法67例(67眼)分别行眼球摘除(32例)或眼内容物剜除(35例)羟基磷灰石义眼座植入术。结果追踪随访观察3￣24月,所有患者外观矫正满意,义眼活动自如与健眼无明显差别,无明显义眼座暴露及排斥反应等并发症发生。结论此手术方法易掌握,术后外形效果良好,是一种理想的眶内植入物。     

视网膜母细胞瘤眼球摘除、羟基磷灰石义眼座Ⅰ期植入临床观察

目的 评价视网膜母细胞瘤眼球摘除，羟基磷灰石（hydroxyopatite，HA）义眼座Ⅰ期植入术后的临床效果。方法 对27例（27眼）Rb患者行眼球摘除眶内HA义眼座Ⅰ期植入术后进行临床观察。结果 术后随访12～36个月，平均18个月。义眼座活动度良好。24例结膜创口Ⅰ期愈合，2例结膜变薄，1例结膜创口裂开，HA义眼座暴露。1例Rb复发。结论 Rb患者眶内HA义眼座Ⅰ期植入有助于眼眶发育和美容。     

羟基磷灰石义眼座植入后义眼座暴露16例分析

目的探讨羟基磷灰石义眼座植入后义眼座暴露的原因。方法历例义眼座暴露分别进行B超检查、CT扫描、手术治疗及术后病理检查。结果16例义服座暴露中，眼眶恶性肿瘤1例，炎性假瘤2例，视网膜母细胞瘤术后局部放疗3例，灭性向芽组织增生10例。结论羟基磷灰石义眼座植入后义眼座暴露的发生宰较低。羟基磷灰石义服座是矫正无眼球眶上区凹陷的一种理想的生物材料。     

视网膜母细胞瘤眼球摘除术后HA义眼座Ⅱ期植入

目的:探讨视网膜母细胞瘤(retinoblastoma,RB)眼球摘除术后羟基磷灰石(hydroxyopatite,HA)眼座Ⅱ期手术的可行性。方法:回顾分析10例10眼眼球摘除术后HA义眼座Ⅱ期植入的临床效果。结果:术后随访1～3a,10例患者中8例患儿结膜创口I期愈合,有1例义眼台暴露,1例结膜肉芽肿。所有患者术后眼窝饱满,义眼活动度良好,外形得到较大改善。结论:RB眼球摘除术后Ⅱ期HA眼座植入可以很好地改善患儿外观,促进眶骨发育。     

眼内容剜除联合多孔羟基磷灰石义眼座植入术临床分析

目的：评价眼内容剜除术联合羟基磷灰石（Hydroxyapatite HA)义眼座植入术的疗效和安全性。方法：1998．1－2000．5在本中心接受眼内容剜除联合HA植入术的78例病例进行回顾性分析。收集各病例临床资料、手术指征、义眼座的大小、手术疗效和术后并发症。平均随诊时间11．6月（2－24月）。结果：本组共78例患者接受眼内容剜除联合HA植入术,全部病例均获得手术成功。术后无一例患者出现义眼座外露、脱出、移位等并发症。随诊期间无交感性眼炎发生。结论：在严格选择手术适应症的条件下,眼内容剜除术联合HA后置植入术是一种安全而有效的治疗部份无光感疼痛性眼球或萎缩眼球的方法。     

羟基磷灰石义眼座Ⅰ期植入矫治眼窝畸形

目的观察羟基磷灰石义眼座Ⅰ期植入矫治眼窝畸形的临床效果。方法分别离断上下内外直肌，剪断视神经，取出眼球，彻底清除眼内色素，植入义眼台，缝合筋膜，缝合球结膜。结果采取此方法矫治眼窝畸形30例取得满意效果。结论羟基磷灰石义眼座Ⅰ期植入此方法简单，能同时达到矫治眼窝畸形与美容的双重效果。     

视网膜母细胞瘤眼球摘除术后羟基磷灰石义眼座Ⅰ期植入

视网膜母细胞瘤(retinoblastoma,RB)是婴幼儿时期最常见的眼内恶性肿瘤,其发病率约为1/15000~1/28000[1],目前我国大部分地区对RB的治疗仍以眼球摘除为主。近年来,羟基磷灰石(hydroxyapatite,HA)义眼座植入已广泛开展,但对RB患者术后是否植入义眼座尤其I期植入,一直存在很大争议。现将2000年1月~2005年5月间的21例RB眼球摘除术后I期植入HA义眼座的临床效果进行分析。1资料与方法1.1一般资料21例(21眼)RB患者,男13例,女8例,年龄6月~5岁,平均3.3岁。左眼12例,右眼9例。就诊原因:白瞳症14例,斜视6例,视力下降1例。所有患儿术前均经CT或…     

M成形术矫正内眦赘皮

目的探讨一种简单有效的内眦赘皮矫正方法。方法应用内眦劈开、插入局部皮瓣和两个三角形皮肤切除的M成形术矫正内眦赘皮46例，其中与重睑同时进行41例，重睑术后内眦开大5例。结果46例内眦赘皮明显的患者术后效果满意。术后1月内有3例出现上睑部增生发红，5例出现内眦部增生发红，4例出现下睑部增生发红。2～3个月后逐渐软化消退。经随访3～12月，疤痕不明显，均获得满意疗效。结论M成形术设计简单、操作容易，术后内眦成形良好，疤痕不明显，值得推广应用。     

眼球摘除联合自体巩膜翻转包裹泡沫硅胶球植入临床应用

目的:观察改进的自体巩膜翻转包裹硅胶义眼植入的效果。方法:眼球摘除术后,将自体巩膜翻转,清除再包绕硅胶球植入术眼结果:30例眼球摘除患者植入此义眼,随访时间6月～3年。义眼活动度10°—25°,有效地防止了眼球摘除术后“空窝综合征”。结论:本术式有效地解决了义眼植入后不能转动的缺点,而且能得到满意的美容效果。眼科学报1995;11:111—112。     

Intraocular inflammation after Ultrasound Cyclo Plasty for the treatment of glaucoma

This is a prospective interventional clinical study evaluating intraocular inflammation developed after Ultrasound Cyclo Plasty (UCP) for the treatment of glaucoma. Eighteen eyes of 18 patients were treated with UCP second-generation probes (Eye OP1). After treatment, the mean intraocular pressure (IOP) significantly decreased from 26.8±7.2 to 18.8±6.1 mm Hg at day 1 and to 14.7±3.4 mm Hg at month 6 (all P<0.001). Mean laser flare-cell photometry value steeply increased after surgery from 12.1±7.5 to 64.1±53.9 ph/ms (P=0.001) at day 1, and then progressively decreased to respectively 60.6±49.7 at day 7, 43.5±38.5 at day 14 and 28.2±18.3 at month 1 (all P<0.05), returning at levels similar to baseline ones at month 3 and month 6 (respectively 16.7±6.2 and 12.8±10.2, both P>0.05). A significant negative correlation was found between postoperative increase of aqueous flare values and anterior chamber depth (R=-0.568, P=0.014). This timeframe may be considered reasonable for repeating UCP treatment, when required.     

High-Density Porous Polyethylene Wedge Implant in Correction of Enophthalmos and Hypoglobus in Seeing Eyes

Introduction: To report the results of post-traumatic enophthalmos/hypophthalmos correction with high-density porous polyethylene wedge implants in seeing eyes.

Methods: This is an interventional case series of 25 patients (25 eyes) with post-traumatic enophthalmos and hypophthalmos, who underwent orbital reconstruction to correct the enophthalmos and hypophthalmos using Medpor^® wedge implant. The aim was an overcorrection of 1?mm in comparison to the other eye, intra-operatively. If needed, trimming of the wedge implant or adding Medpor^® sheets were used to achieve the goal. Success was defined as achieving the globe position within 1?mm of the other eye in the last follow-up. Improvement and failure were considered as correction outside the success range of 1?mm and no change in the amount of enophthalmos/hypophthalmos, respectively.

Results: Patients were followed for at least 6 months (mean= 12.66, SD= 12.32). Success, improvement and failure of enophthalmos correction were: 58.3% (14/24), 37.5% (9/24) and 1 (1/24, 4.1%), respectively. Success, improvement and failure of hypophthalmos correction were 73.68% (14/19), 15.78% (3/19) and 5.26% (1/19), respectively. There was no significant difference between the success rate of enophthalmos versus hypophthalmos correction (P= 0.8). Results of 1-month follow up change in enophthalmos and hypophthalmos significantly correlated (r= 0.92, P= 0.000) with the change recorded at last follow up.

Conclusions: Porous polyethylene wedge implants are useful and safe in correction of enophthalmos and hypoglobus in seeing eyes. Appropriately positioned implant yields no significant difference in correction of enophthalmos versus hypophthalmos.     

Treatment of Serpiginous Choroiditis with Intravitreous Fluocinolone Acetonide Implant

Purpose: To describe a case in which a fluocinolone acetonide implant was used in a patient with serpiginous choroiditis. Design: Case report. Results: A 57-year-old woman with active serpiginous choroiditis threatening the fovea of her right eye received one intravitreous triamcinolone acetonide injection, leading to immediate disease control. An intravitreous fluocinolone acetonide implant was placed, and resulted in ongoing control of the disease as of her 14 months postoperative follow-up. Conclusions: Intravitreous fluocinolone acetonide implant should be recognized as a potential treatment option for serpiginous choroiditis.